As of 2024-07-27, the Relative Valuation of BioCryst Pharmaceuticals Inc (BCRX) is (31.84) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.85 USD, the upside of BioCryst Pharmaceuticals Inc based on Relative Valuation is -505.6%.
The range of the Relative Valuation is (31.53) - (32.63) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.2x - 41.3x | 31.8x |
| Forward P/E multiples | 30.5x - 32.3x | 31.2x |
| Fair Price | (31.53) - (32.63) | (31.84) |
| Upside | -501.7% - -515.6% | -505.6% |
| Date | P/E |
| 2024-07-26 | -7.77 |
| 2024-07-25 | -7.47 |
| 2024-07-24 | -7.32 |
| 2024-07-23 | -7.39 |
| 2024-07-22 | -7.34 |
| 2024-07-19 | -7.06 |
| 2024-07-18 | -6.98 |
| 2024-07-17 | -7.19 |
| 2024-07-16 | -7.55 |
| 2024-07-15 | -7.10 |
| 2024-07-12 | -7.07 |
| 2024-07-11 | -6.97 |
| 2024-07-10 | -6.42 |
| 2024-07-09 | -6.41 |
| 2024-07-08 | -6.35 |
| 2024-07-05 | -6.45 |
| 2024-07-03 | -6.34 |
| 2024-07-02 | -6.48 |
| 2024-07-01 | -6.60 |
| 2024-06-28 | -6.11 |
| 2024-06-27 | -6.05 |
| 2024-06-26 | -6.11 |
| 2024-06-25 | -6.02 |
| 2024-06-24 | -6.20 |
| 2024-06-21 | -6.35 |
| 2024-06-20 | -6.08 |
| 2024-06-18 | -5.94 |
| 2024-06-17 | -6.17 |
| 2024-06-14 | -6.10 |
| 2024-06-13 | -6.16 |
| 2024-06-12 | -6.23 |
| 2024-06-11 | -6.41 |
| 2024-06-10 | -6.45 |
| 2024-06-07 | -6.24 |
| 2024-06-06 | -6.37 |
| 2024-06-05 | -6.72 |
| 2024-06-04 | -6.67 |
| 2024-06-03 | -6.72 |
| 2024-05-31 | -6.39 |
| 2024-05-30 | -6.50 |
| 2024-05-29 | -6.08 |
| 2024-05-28 | -6.12 |
| 2024-05-24 | -6.07 |
| 2024-05-23 | -6.26 |
| 2024-05-22 | -6.59 |
| 2024-05-21 | -6.35 |
| 2024-05-20 | -6.07 |
| 2024-05-17 | -6.21 |
| 2024-05-16 | -6.40 |
| 2024-05-15 | -6.29 |